Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies

Diabetes Care

Volumn 35, Issue 6, 2012, Pages 1213-1218

  Yu, Liping ^a   Boulware, David C ^b   Beam, Craig A ^b   Hutton, John C ^a   Wenzlau, Janet M ^a   Greenbaum, Carla J ^c   Bingley, Polly J ^d   Krischer, Jeffrey P ^b   Sosenko, Jay M ^e   Skyler, Jay S ^e   Eisenbarth, George S ^a   Mahon, Jeffrey L ^f  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF MIAMI   (United States)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; CELL ANTIBODY; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; INSULIN ANTIBODY; INSULINOMA ASSOCIATED PROTEIN 2 ANTIGEN; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8 ANTIBODY;

ADULT; AGE DETERMINATION; ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; FEMALE; HLA SYSTEM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; RELATIVE; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AUTOANTIBODIES; CATION TRANSPORT PROTEINS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FAMILY; FEMALE; GENOTYPE; GLUCOSE TOLERANCE TEST; HUMANS; INFANT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84861761425     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2081     Document Type: Article

References (23)

1. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010;95:25-33
2. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691
3. Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925-931
4. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care 2005;28:1068-1076 (Pubitemid 40616615)
5. Skyler JS, Greenbaum CJ, Lachin JM, et al.; Type 1 Diabetes TrialNet Study Group. Type 1 Diabetes TrialNet - an international collaborative clinical trials network. Ann N Y Acad Sci 2008;1150: 14-24
6. Knip M, Virtanen SM, Seppä K, et al.; Finnish TRIGR Study Group. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med 2010;363:1900-1908
7. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007; 104:17040-17045 (Pubitemid 350210987)
8. Achenbach P, Lampasona V, Landherr U, et al. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009;52: 1881-1888
9. De Grijse J, Asanghanwa M, Nouthe B, et al.; Belgian Diabetes Registry. Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 2010; 53:517-524
10. Orban T, Sosenko JM, Cuthbertson D et al.; Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32:2269-2274
11. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al.; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 2009;10:97-104
12. Mychaleckyj JC, Noble JA, Moonsamy PV, et al.; T1DGC. HLA genotyping in the international Type 1 Diabetes Genetics Consortium. Clin Trials 2010;7(Suppl.): S75-S87
13. Wang J, Miao D, Babu S, et al. Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 2007;92:88-92 (Pubitemid 46075008)
14. Schatz D, Krischer J, Horne G, et al. Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives. J Clin Invest 1994;93:2403-2407 (Pubitemid 24177152)
15. Verge CF, Stenger D, Bonifacio E, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 1998;47:1857-1866 (Pubitemid 28549191)
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus (Position Statement). Diabetes Care 2009; 39(Suppl. 1):S62-S67
17. Lampasona V, Petrone A, Tiberti C, et al.; Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study Group. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4. Diabetes Care 2010;33:104-108
18. Vermeulen I, Weets I, Asanghanwa M, et al.; Belgian Diabetes Registry. Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care 2011;34:1760-1765
19. Achenbach P, Bonifacio E, Williams AJ, Ziegler AG, Gale EA, Bingley PJ; ENDIT Group. Autoantibodies to IA-2b improve diabetes risk assessment in high-risk relatives. Diabetologia 2008;51:488-492
20. Sosenko JM, Skyler JS, Mahon J, et al.; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787
21. Bingley PJ, Mahon JL, Gale EA; European Nicotinamide Diabetes Intervention Trial Group. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008;31:146-150
22. Stene LC, Barriga K, Hoffman M, et al. Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Pediatr Diabetes 2006;7:247-253 (Pubitemid 44593924)
23. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995;48:1503-1510 (Pubitemid 26035533)